NCT07603193Enrolling by invitation
Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream
Prospective, Non-interventional, Multicenter Real-world Evidence Study on Effectiveness and Safety of Treatment of Patients With Moderate to Severe Chronic Hand Eczema With Delgocitinib Cream (20mg/g)
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
The goal of this non-interventional study is to assess changes in the signs and symptoms of Chronic Hand Eczema (CHE), as well as the safety profile and use of delgocitinib cream in routine clinical practice, over a 52-week observation period. The main question it aims to answer is: Does delgocitinib cream show effectiveness in routine clinical practice in adult patients with moderate to severe Chronic Hand Eczema (CHE), as measured by achievement of a modified Physician Global Assessment (mPGA) score of 0 or 1? The decision to prescribe delgocitinib cream is made by the treating physician, as part of the participant's routine medical care for CHE.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 7 May 2026
- Start date
- 1 Jun 2025
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- LEO Pharma
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07603193
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Jun 2025 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous enrolment in this non-interventional study.
- Previous treatment with delgocitinib cream.
Other
- Currently enrolled in an interventional clinical trial, or have participated in an interventional clinical trial in the past year from the date of enrolment
Who the study is looking for
- Written informed consent to participate in this study and for collecting and analysing medical data pertinent to the study objectives.
- Age ≥18 years
- Patients diagnosed with CHE who are eligible for treatment with delgocitinib cream as per the physician's clinical discretion.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| LEO Pharma Coordinator of this site? Confirm its status | Neu-Isenburg | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.